Stock Yearly Return 2020
Start date: 12/31/2019
End date: 12/31/2020
Start price/share: $22.96
End price/share: $29.73
Dividends collected/share: $0.00
Total return: 29.49%
Average Annual Total Return: 29.39%
Starting investment: $10,000.00
Ending investment: $12,948.14
Years: 1.00

RYTM average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare RYTM average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into RYTM

Also see:
RYTM YTD return
RYTM average annual return 10 years
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the treatment of rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger or hyperphagia. Co.'s main product candidate is IMCIVREE (setmelanotide), a melanocortin-4 receptor, agonist for the treatment of rare genetic diseases of obesity. IMCIVREE has been approved by the U.S. Food and Drug Administration for chronic weight management in adult and pediatric patients six years of age and older with obesity due to proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, leptin receptor, deficiency confirmed by genetic testing. The RYTM stock yearly return is shown above.

The yearly return on the RYTM stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2020 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the RYTM annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for RYTM:
RYTM SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Rhythm Pharmaceuticals (RYTM) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

SAGE Average Annual Return
SBPH Average Annual Return
SCPH Average Annual Return
SCYX Average Annual Return
SELB Average Annual Return
SEM Average Annual Return
SGEN Average Annual Return
SGMO Average Annual Return
SGRY Average Annual Return
SGYP Average Annual Return
More Healthcare companies »


RYTM Stock Yearly Return 2020 | | Copyright © 2021 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.